![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Optimer Pharmaceuticals sells its OBI division to Taiwanese investment consortium for $60mm
Executive Summary
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice